IMS Pharmacoeconomics report
Overview
Unlocking the potential of evidence-based medicine in a cost-contained market.

This new report covers the expanding role of pharmacoeconomics in pharmaceutical pricing and reimbursement decisions in key markets and its role in the product life cycle. It is designed to provide indispensable reference material in a format that allows easy comparison between countries.

Contents

Australia, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Norway, Netherlands, Spain, Sweden, Switzerland, UK, USA.

Contact Us
For more information about this offering, please contact us or call us at +44 (207) 393 5888